EC approves AstraZeneca's Zinforo
The European Commission's marketing authorisation is based on data from the phase III clinical trial programme which included four pivotal registration trials.
AstraZeneca says the authorisation makes Zinforo the only only approved cephalosporin monotherapy in Europe with demonstrated clinical efficacy against methicillin-resistant Staphylococcus aureus (MRSA), a common cause of serious and difficult to treat complicated skin infections.
At 10:00am: [LON:AZN] AstraZeneca share price was -5.5p at 2976p
Story provided by StockMarketWire.com